The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Open accessPublished version of a preprint
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired a D614G mutation early in the pandemic that confers greater infectivity and is now the globally dominant form. To determine whether D614G might also mediate neutralization escape that could compromise vaccine efficacy, sera from spike-immunized mice, nonhuman primates, and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 spike. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by receptor-binding domain (RBD) monoclonal antibodies and convalescent sera from people infected with either form of the virus. Negative stain electron microscopy revealed a higher percentage of the 1-RBD "up" conformation in the G614 spike, suggesting increased epitope exposure as a mechanism of enhanced vulnerability to neutralization. Based on these findings, the D614G mutation is not expected to be an obstacle for current vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to previous studies from our group (15) and others (18), pseudovirus neutralization titers to D614G were threefold higher than to WA1 (Fig. 2G).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKorber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 4×
“This is the immunogen being employed in the Moderna vaccine in phase 3 clinical trials (mRNA1273, NCT04470427) (Jackson et al., 2020).”
InfluentialCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Self-citationCross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Cited by
Sorted by citations
Items 201–300 of 332
Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines
Tsiambas, E., Chrysovergis, A., PAPANIKOLAOU, V. S., MASTRONIKOLIS, N. S., Ragos, V., Batistatou, A. K., Peschos, D., Kavantzas, N., Lazaris, A. C., & Kyrodimos, E. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.654866 · Cited by 11
Pokhrel, S., Kraemer, B. R., Lee, L., Samardzic, K., & Mochly‐Rosen, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251426 · Cited by 12
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · ACS Omega · doi:10.1021/acsomega.1c02336 · Cited by 10
Devaux, C. A., & Fantini, J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1199561 · Cited by 10
Dang, S., Ren, L., & Wang, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002158 · Cited by 10
Alter, G., Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-200342/v1 · Cited by 9
Self-citationHarfoot, R., Lawley, B., Hernández, L. C., Kuang, J., Grant, J., Treece, J. M., Lequeux, S., Day, R. C., Jack, S. J., Stanton, J. L., et al. (2022) · Viruses · doi:10.3390/v14020366 · Cited by 10
Development of DNA Vaccine Candidate against SARS-CoV-2
Wang, X., Rcheulishvili, N., Cai, J., Liu, C., Xie, F., Hu, X., Yang, N., Hou, M., Papukashvili, D., He, Y., et al. (2022) · Viruses · doi:10.3390/v14051049 · Cited by 10
Deval, H., Nyayanit, D. A., Mishra, S., Yadav, P., Zaman, K., Shankar, P., Misra, B., Behera, S., Kumar, N., Kumar, A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.781287 · Cited by 11
Sulbarán, G., Maisonnasse, P., Amen, A., Effantin, G., Guilligay, D., Dereuddre‐Bosquet, N., Burger, J. A., Poniman, M., Grobben, M., Buisson, M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100528 · Cited by 11
Fears, A. C., Beddingfield, B. J., Chirichella, N. R., Slisarenko, N., Killeen, S. Z., Redmann, R. K., Goff, K. A., Spencer, S., Picou, B., Golden, N., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010618 · Cited by 8
Self-citationAhmad, W., Ahmad, S., & Basha, R. M. (2022) · Gene · doi:10.1016/j.gene.2022.146774 · Cited by 9
Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Cases Corroborated by Sequencing
Massachi, J., Donohue, K. C., & Kelly, J. D. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-0365 · Cited by 8
Li, J., Liang, T., Hei, A., Wang, X., Li, H., Yu, X., Zhao, R., Gao, P., Fang, C., Zhou, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074077 · Cited by 8
Recordon-Pinson, P., Blondot, M.-L., Bellecave, P., Lafon, M., Tumiotto, C., Métifiot, M., & Andréola, M. (2021) · COVID · doi:10.3390/covid1010028 · Cited by 9
Tao, K., Tzou, P. L., Pond, S. L. K., Ioannidis, J. P. A., & Shafer, R. W. (2022) · Preprints.org · doi:10.20944/preprints202203.0155.v1 · Cited by 9
Boix‐Besora, A., Gòdia, F., & Cervera, L. (2023) · Vaccines · doi:10.3390/vaccines11111641 · Cited by 9
TONG, J. J., Zhu, C., Lai, H., Feng, C., & Zhou, D. (2021) · Vaccines · doi:10.3390/vaccines9030296 · Cited by 8
Zhang, L., Li, Q., Wu, J., Yu, Y., Zhang, Y., Nie, J., Liang, Z., Cui, Z., Liu, S., Wang, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2054369 · Cited by 10
Wang, C., Elghobashi‐Meinhardt, N., & Balch, W. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.07.475295 · Cited by 9
D614G reshapes allosteric networks and opening mechanisms of SARS-CoV-2 spikes
Kearns, F. L., Bogetti, A. T., Calvó‐Tusell, C., Braza, M. K. E., Casalino, L., Gramm, A. J., Braet, S. M., Rosenfeld, M. A., Rajapaksha, H., Barker, B., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2504793123 · Cited by 7
Identification of genotypic variants and its proteomic mutations of Brazilian SARS-CoV-2 isolates
Prathiviraj, R., Chellapandi, P., Begum, A., Kiran, G. S., & Selvin, J. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198618 · Cited by 7
Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors
Huang, L., Zhu, L., Xie, H., Goodwin, J. S., Rana, T., Xie, L., & Chen, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179659 · Cited by 7
Allosteric communication between ACE2 active site and binding interface with SARS-CoV-2
Mugnai, M. L., & Thirumalai, D. (2023) · The Journal of Chemical Physics · doi:10.1063/5.0137654 · Cited by 7
Ruiz-Rodríguez, P., Francés-Gómez, C., Chiner‐Oms, Á., López, M. G., Jiménez-Serrano, S., Cancino‐Muñoz, I., Ruiz-Hueso, P., Torres‐Puente, M., Bracho, M. A., D’Auria, G., et al. (2021) · mBio · doi:10.1128/mbio.02315-21 · Cited by 8
Biswas, S., Mahmud, S., Mita, M. A., Afrose, S., Hasan, M. R., Paul, G. K., Shimu, M. S. S., Uddin, M. S., Zaman, S., Park, M. N., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.825245 · Cited by 6
Kinetics and Correlates of the Neutralizing Antibody Response to SARS-CoV-2Preprint
Vanshylla, K., Cristanziano, V. D., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M. S., Stumpf, R., et al. (2021) · SSRN Electronic Journal · doi:10.1101/2021.01.26.428207 · Cited by 7
Teruel, N., Crown, M. R., Rajsbaum, R., Bashton, M., & Najmanovich, R. (2025) · Virus Evolution · doi:10.1093/ve/veaf027 · Cited by 7
In Silico Analysis of SARS-CoV-2 Spike Proteins of Different Field Variants
Haseeb, M., Amir, A., & Ikram, A. (2023) · Vaccines · doi:10.3390/vaccines11040736 · Cited by 7
Kim, T.-H., Bae, S., Goo, S., & Myoung, J. (2023) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2308.08020 · Cited by 6
Development of a SARS‐CoV‐2 neutralization assay based on a pseudotyped virus using a HIV system
Liang, Z., Tong, J., Wu, X., Liu, S., Wu, J., Yu, Y., Zhang, L., Zhao, C., Lu, Q., Nie, J., et al. (2024) · MedComm · doi:10.1002/mco2.517 · Cited by 6
Malune, P., Piras, G., Monne, M. I., Fiamma, M., Asproni, R., Fancello, T., Manai, A. L., Carta, F., Pira, G., Fancello, P., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.827799 · Cited by 6
Stromberg, Z. R., Theiler, J. P., Foley, B. T., y Gutiérrez, A. M., Hollander, A., Courtney, S. J., Gans, J. D., Deshpande, A., Martinez‐Finley, E. J., Mitchell, J., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000207 · Cited by 6
Enhancing the Immunogenicity of RBD Protein Variants through Amino Acid E484 Mutation in SARS-CoV-2
Zhang, Z., Wan, X., Li, X., Cai, S.-X., & Wan, C. (2022) · Viruses · doi:10.3390/v14092020 · Cited by 6
Delta variant: Partially sensitive to vaccination, but still worth global attention
Zhang, M., He, Y.-C., & Jie, Z. (2022) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2022-0026 · Cited by 6
Advancements in the Development of Anti-SARS-CoV-2 Therapeutics
Huang, J., Ma, Q., Su, Z., & Cheng, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910820 · Cited by 5
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031646 · Cited by 5
Diversidad genómica en SARS-CoV-2: Mutaciones y variantes
Aguilar–Gamboa, F. R., Suclupe-Campos, D. O., Vega-Fernández, J. A., & Silva-Díaz, H. (2021) · Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo · doi:10.35434/rcmhnaaa.2021.144.1465 · Cited by 5
Efficacy of Plant-Made Human Recombinant ACE2 against COVID-19 in a Golden Syrian Hamster Model
Kim, C., Kim, D., Bang, M.-S., Seo, J.-W., Kim, D., Yun, N. R., Lim, S., Lee, J. H., Sohn, E., Kang, H., et al. (2023) · Viruses · doi:10.3390/v15040964 · Cited by 5
Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines
Wang, S., Wu, D., Xiong, H., Wang, J., Tang, Z., Chen, Z., Wang, Y., Zhang, Y., Dong, Y., Lin, X. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952650 · Cited by 7
Liu, W.-D., Wang, J., Chao, T., Ieong, S., Tsai, Y., Kuo, P.-H., Tsai, M.-J., Chen, Y.-J., Li, G.-C., Ho, S., et al. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.11.015 · Cited by 5
Abduljaleel, Z., Melebari, S., Athar, M., Dehlawi, S., Kumar, S., Aziz, S. A. A., Dannoun, A., Malik, S. M., Thasleem, J., & Doss, C. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110798 · Cited by 5
Small-world effects in a modified epidemiological model with mutation and permanent immune mechanism
Cao, S., Feng, P., Wang, W., Shi, Y., & Zhang, J. (2021) · Nonlinear Dynamics · doi:10.1007/s11071-021-06519-8 · Cited by 4
Sokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.17.448459 · Cited by 5
Profiling of SARS-CoV-2 Subgenomic RNAs in Clinical SpecimensPreprint
Chen, Z., Ng, R. W. Y., Lui, G. C.-Y., Ling, L., Chow, C., Yeung, A. C. M., Boon, S. S., Wang, M. H., Chan, K. C. C., Chan, R. W. Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3987999 · Cited by 5
Ferrareze, P. A. G., Zimerman, R. A., Franceschi, V. B., Caldana, G. D., Netz, P. A., & Thompson, C. E. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2076154 · Cited by 4
The impact of host microRNAs on the development of conserved mutations of SARS-CoV-2
Ghaemi, S., Abdoli, A., Karimi, H., Saadatpour, F., & Arefian, E. (2024) · Scientific Reports · doi:10.1038/s41598-024-70974-7 · Cited by 4
Genomic and spatial epidemiology: lessons learned from SARS-CoV-2 pandemic
Choi, Y., Ridder, D. D., & Greub, G. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000936 · Cited by 4
Abavisani, M., Rahimian, K., Kodori, M., Khayami, R., Sisakht, M. M., Mahmanzar, M., & Meshkat, Z. (2022) · PubMed Central · doi:10.22038/ijbms.2022.66649.14620 · Cited by 4
de la Rosa, D., López-Campos, J. L., Blanco‐Aparicio, M., & Álvarez, F. V. (2021) · Vacunas · doi:10.1016/j.vacun.2021.05.001 · Cited by 4
Manh, D. H., Lan, P. T., Cao, T. M., Lương, Q. C., Pham, H., Vu, N. H. P., Khuu, N. V., Nguyen, T. V., Nguyễn, L. T., Nguyen, H. T., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27103 · Cited by 4
Yokoyama, K., Lam, T., Santariello, J., & Ichiki, A. (2022) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2022.128967 · Cited by 4
Sarkar, R., Chawla‐Sarkar, M., Majumdar, S., Lo, M., & Chattopadhyay, S. (2021) · medRxiv · doi:10.1101/2021.05.25.21257434 · Cited by 4
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spikePreprint
Díaz-Salinas, M. A., Li, Q., Ejemel, M., Yurkovetskiy, L., Luban, J., Shen, K., Wang, Y., & Munro, J. B. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.29.466470 · Cited by 4
Vassilaki, N., Papadimitriou, K., Ioannidis, A., Papandreou, N. C., Milona, R. S., Iconomidou, V. A., & Chatzipanagiotou, S. (2022) · Microorganisms · doi:10.3390/microorganisms10071430 · Cited by 3
Effect of mutations on stochastic dynamics of infectious diseases, a probability approach
RabieiMotlagh, O., & Soleimani, L. (2023) · Applied Mathematics and Computation · doi:10.1016/j.amc.2023.127993 · Cited by 3
Multiplexed discrimination of SARS-CoV-2 variants via duplex-specific nuclease combined MALDI-TOF MS
Han, G., Deng, W., Lyu, Q., Ma, Q., & Qiao, L. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05202-2 · Cited by 3
Maison, D. P., Cleveland, S. B., & Nerurkar, V. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278287 · Cited by 3
Phylogeny and evolution of SARS-CoV-2 during Delta and Omicron variant waves in India
Singh, U. B., Deb, S., Rani, L., Gupta, R., Verma, S., Kumari, L., Bhardwaj, D., Bala, K., Ahmed, J., Gourav, S., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2222832 · Cited by 6
An update on vaccine status and the role of nanomedicine against SARS‐CoV‐2: A narrative review
Tajnur, R., Rezwan, R., Aziz, M. A., & Islam, M. S. (2023) · Health Science Reports · doi:10.1002/hsr2.1377 · Cited by 2
Mutation Analysis of SARS-CoV-2 Variants Isolated from Symptomatic Cases from Andhra Pradesh, India
Mudhigeti, N., Sireesha, K., Srikar, A., Katari, S. K., Mohan, A., Vengamma, B., Tirumala, C., Verma, A., & Kalawat, U. (2023) · Viruses · doi:10.3390/v15081656 · Cited by 3
Lysosomal “TRAP”: a neotype modality for clearance of viruses and variants
Lyu, C., He, Z., Hu, X., Wang, S., Qin, M., Zhu, L., Li, Y., Yang, F., Jiao, Z., Zhang, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54505-6 · Cited by 4
Sequence similarity of SARS-CoV-2 and humans: Implications for SARS-CoV-2 detection
Li, H., Hong, X., Ding, L., Meng, S., Liao, R., Jiang, Z., & Liu, D. J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.946359 · Cited by 5
Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19
Liu, W.-D., Hung, C., Wang, J., Tsai, M.-J., Kuo, P.-H., Chao, T., Hsieh, S., Sheng, W., Chen, Y., Chang, S., et al. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.04.010 · Cited by 3
A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States
Capoferri, A. A., Shao, W., Spindler, J., Coffin, J. M., Rausch, J. W., & Kearney, M. F. (2022) · Viruses · doi:10.3390/v14010104 · Cited by 3
Broadly neutralizing antibodies against SARS-CoV-2 variants
Zhang, L. (2022) · National Science Open · doi:10.1360/nso/20220005 · Cited by 3
Emergence of SARS-CoV-2 stains harbouring the signature mutations of both A2a and A3 cladePreprint
Sarkar, R., Banerjee, A., Dutta, S., & Chawla‐Sarkar, M. (2021) · medRxiv · doi:10.1101/2021.02.04.21251117 · Cited by 3
Ge, A., Rioux, M. L., & Kelvin, A. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.25.437035 · Cited by 3
Impact of glycosylation on a broad-spectrum vaccine against SARS-CoV-2Preprint
Huang, H.-Y., Liao, H.-Y., Chen, X., Wang, S.-W., Cheng, C.-W., Shahed-Al-Mahmud, M., Chen, T.-H., Lo, J. M., Liu, Y.-M., Wu, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.25.445523 · Cited by 3
Choudhary, A. K., Lerman, M. J., Calianese, D. C., Khan, S., Hunt, J. M., Nikaein, A., Rosenberg, A. Z., Silverberg, J. I., Zyskind, I., Honnen, W. J., et al. (2022) · medRxiv · doi:10.1101/2022.02.10.22270607 · Cited by 3
SARS-CoV-2 Omicron Variant Wave in India: Advent, Phylogeny and EvolutionPreprint
Singh, U. B., Deb, S., Chaudhry, R., Bala, K., Rani, L., Gupta, R., Kumari, L., Ahmed, J., Gaurav, S., Perumalla, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.14.491911 · Cited by 3
Application of Orthoflavivirus Pseudovirus Technology in Antiviral Research
Zhang, Y., Zhao, Y., Wang, C., Zhou, Y., Yuan, H., Li, X., Wang, Y. M., & Pan, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020722 · Cited by 2
Zhao, S., Lou, J., Cao, L., Zheng, H., Chong, K. C., Chen, Z., Chan, R. W. Y., Zee, B. C.-Y., Chan, P. K. S., & Wang, M. H. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06729-w · Cited by 2
Jaishwal, P., Gyaneshwari, U., Jha, K., Pandey, B., Yadav, T. P., & Singh, S. P. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.90 · Cited by 2
Host cell entry efficiency and neutralization sensitivity of the SARS-CoV-2 MC.10.1 variant
Zhang, L., Kempf, A. M., Nehlmeier, I., Chen, N., Graichen, L., Moldenhauer, A.-S., Stankov, M. V., Happle, C., Schulz, S. R., Dopfer‐Jablonka, A., et al. (2025) · Virology · doi:10.1016/j.virol.2025.110675 · Cited by 2
Gazali, F. M., Wijayanti, N., Hakim, M. S., Supriyati, E., Arguni, E., Daniwijaya, M. E. W., Nuryastuti, T., Nuhamunada, M., Nabilla, R., Haryana, S. M., et al. (2023) · VirusDisease · doi:10.1007/s13337-023-00827-w · Cited by 2
SEPAR recommendations and new challenges on COVID-19 vaccine in respiratory diseases
de la Rosa, D., López-Campos, J. L., Blanco‐Aparicio, M., & Álvarez, F. V. (2021) · Vacunas (English Edition) · doi:10.1016/j.vacune.2021.10.001 · Cited by 2
Codon usage, phylogeny and binding energy estimation predict the evolution of SARS-CoV-2
Calcagnile, M., Verri, T., Tredici, M. S., Forgez, P., Alifano, M., & Alifano, P. (2021) · One Health · doi:10.1016/j.onehlt.2021.100352 · Cited by 2
Research Methodology to Define the Introduction of the SARS-CoV-2 B.1.429 Variant in HawaiiPreprint
Maison, D. P., & Nerurkar, V. R. (2021) · Research Square · doi:10.21203/rs.3.rs-378702/v1 · Cited by 2
Wang, S.-L., Wu, D.-H., Xiong, H.-L., Wang, J., Tang, Z., Chen, Z.-H., Wang, Y.-Z., Zhang, Y.-L., Ying, D., Lin, X., et al. (2021) · bioRxiv · doi:10.1101/2021.04.10.439161 · Cited by 2
Infectivity and antigenicity of SARS-CoV-2 B.1.617 variantsPreprint
Wang, Y., Zhang, L., Li, Q., Wu, J., Yu, Y., Zhang, Y., Nie, J., Liang, Z., Cui, Z., Liu, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-596463/v1 · Cited by 2
Maison, D. P., Cleveland, S. B., & Nerurkar, V. R. (2021) · Research Square · doi:10.21203/rs.3.rs-378702/v3 · Cited by 2
Evolutionary aspect of spike glycoprotein's conformational dynamics
Xu, W., Guo, T., & Su, H. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp04391c · Cited by 1
SARS-CoV-2 vaccines from A to Z: A Review of the current challenges
Albalaty, J. M., Forsan, F. H., Awad, S., et al. (2023) · Global NEST Journal · doi:10.30955/gnj.004651 · Cited by 1
Beddingfield, B. J., Maness, N. J., Spencer, S., Rappaport, J., Aye, P. P., Russell‐Lodrigue, K., Doyle‐Meyers, L. A., Blair, R. V., Gao, H., Montefiori, D. C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1085883 · Cited by 1
Self-citationTakeda, M. (2023) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2023.353 · Cited by 1
Causes and Consequences of Coronavirus Spike Protein Variability
Zech, F., Jung, C., Jacob, T., & Kirchhoff, F. (2024) · Viruses · doi:10.3390/v16020177
Garg, P. (2021) · Nano LIFE · doi:10.1142/s1793984421300107 · Cited by 2
Organizational and management solutions to control the spread of COVID-19
Trunin, A., Chudinov, I. K., Lebedeva, V., Aleshina, D., Ilina, A., Shirobokov, Y. E., & Melerzanov, A. (2021) · Vrach · doi:10.29296/25877305-2021-07-01 · Cited by 1
Systematic Review of COVID-19 Treatment and Management
Tonycheta, C. G. (2021) · Baltic Journal of Sport and Health Sciences · doi:10.33607/bjshs.v3i122.1107 · Cited by 1
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2Preprint
Klein, F., Vanshylla, K., Cristanziano, V. D., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M. S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-148929/v1 · Cited by 1
Pokhrel, S., Lee, L., Kraemer, B. R., Samardzic, K., & Mochly‐Rosen, D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.19.427355 · Cited by 1
Maison, D. P., Cleveland, S. B., & Nerurkar, V. R. (2021) · Research Square · doi:10.21203/rs.3.rs-378702/v2 · Cited by 1
Fears, A. C., Beddingfield, B. J., Chirichella, N. R., Slisarenko, N., Killeen, S. Z., Redmann, R. K., Goff, K. A., Spencer, S., Picou, B., Golden, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.28.470250 · Cited by 1
Self-citationAntibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and AgePreprint
Murrell, A. E., Eyoh, E., Shaffer, J. G., Dietrich, M. L., Trinh, I. V., Yockachonis, T. J., Bai, S., Zheng, C. Y., Mayne, C. V., Cabrera, S. E., et al. (2022) · medRxiv · doi:10.1101/2022.04.22.22274032 · Cited by 1
In-silico Analysis of SARS-Cov2 Spike Proteins of Different Field VariantsPreprint
Haseeb, M., Amir, A., & Ikram, A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.22.525048 · Cited by 1
Virus genomics as a clinical and epidemiological tool
Petrone, M. E. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103141
Pamukcu, C., Çelik, E., Ergun, E. Z., Karahan, Z. S., Turkoz, G., Aras, M., Eren, C., Sili, U., Bilgin, H., Süder, İ., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.28.424590
mRNA Based SARS-CoV-2 Vaccines and Ongoing Researches
Hoşbul, T., Yılmaz, Ü. İ., Aydoğan, C. N., & Şahiner, F. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.20
Network analysis outlines strengths and weaknesses of emerging SARS-CoV-2 Spike variantsPreprint
Manrique, P. D., Chakraborty, S., Nguyen, K., Mansbach, R. A., Korber, B., & Gnanakaran, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.03.458946
Self-citation
Metadata
- Authors
- Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., Mansouri, K., Gobeil, S., McDanal, C., Pardi, N., Hengartner, N., Lin, P. J. C., Tam, Y., Shaw, P. A., Lewis, M. G., Boesler, C., Şahin, U., Acharya, P., Haynes, B. F., Korber, B., & Montefiori, D. C.
- Affiliations
- University of Pennsylvania (US)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- University of Sheffield (GB)
- Duke University (US)
- Beth Israel Deaconess Medical Center (US)
- Acuitas Therapeutics (Canada) (CA)
- Bioqual (US)
- BioNTech (Germany) (DE)
- Los Alamos National Laboratory (US)
- Corresponding author
- Weissman, Drew
- ORCID
- Weissman, Drew
- Alameh, Mohamad-Gabriel
- Collini, Paul
- Hornsby, Hailey
- Brown, Rebecca
- LaBranche, Celia C.
- Edwards, Robert J.
- Sutherland, Laura
- Santra, Sampa
- Mansouri, Katayoun
- Gobeil, Sophie
- McDanal, Charlene
- Pardi, Norbert
- Lin, Paulo J.C.
- Tam, Ying
- Shaw, Pamela A.
- Lewis, Mark G.
- Boesler, Carsten
- Şahin, Uğur
- Acharya, Priyamvada
- Haynes, Barton F.
- Korber, Bette
- Montefiori, David C.
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 29
- Issue
- 1
- Pages
- 23-31.e4
- ISSN
- 1931-3128 (ISSN-L)
- PMC
- PMC7707640
- OpenAlex
- W3108737416
- Cited by
- 324
- References
- 57
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 17 · 2023: 33 · 2022: 72 · 2021: 173
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell Host & Microbe (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- National Institutes of Health (75N93019C00050, HHSN272201800004C, R01 - AI145687)
- Wellcome Trust (110058/Z/15/Z)
- National Institute of Allergy and Infectious Diseases (AI142596, AI124429, R01AI123738, 1R01AI146101)
- University of Pennsylvania
- National Institute for Health Research
- Laboratory Directed Research and Development (20200706ER)
- Bill and Melinda Gates Foundation (OPP1146996)
- UK Research and Innovation
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, spike protein, D614G mutation, neutralizing antibodies, neutralization escape, receptor binding domain, monoclonal antibodies, convalescent sera, epitope exposure, vaccine efficacy, pseudovirus
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Serotherapy, Adolescent, Adult, Animals, Antibodies, Monoclonal, Binding Sites, Female, Humans, Immunization, Passive, Macaca mulatta, Male, Mice, Inbred BALB C, Middle Aged, Mutation, Neutralization Tests, Mice, Young Adult, HEK293 Cells, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
